Show simple item record

dc.contributor.authorDoyle, JS
dc.contributor.authorAspinall, E
dc.contributor.authorLiew, D
dc.contributor.authorThompson, AJ
dc.contributor.authorHellard, ME
dc.date.available2014-05-22T08:19:47Z
dc.date.available2012-08-07
dc.date.available2012-08-07
dc.date.available2012-08-07
dc.date.available2012-08-07
dc.date.available2012-08-07
dc.date.available2012-08-07
dc.date.available2012-08-07
dc.date.issued2013-04-01
dc.identifierhttp://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000316326200005&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=d4d813f4571fa7d6246bdc0dfeca3a1c
dc.identifier.citationDoyle, J. S., Aspinall, E., Liew, D., Thompson, A. J. & Hellard, M. E. (2013). Current and emerging antiviral treatments for hepatitis C infection. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 75 (4), pp.931-943. https://doi.org/10.1111/j.1365-2125.2012.04419.x.
dc.identifier.issn0306-5251
dc.identifier.urihttp://hdl.handle.net/11343/33201
dc.descriptionC1 - Journal Articles Refereed
dc.description.abstractNewly licensed direct acting antivirals for hepatitis C virus HCV are able to cure up to 75% of patients chronically infected with genotype-1 infection, which is the predominant HCV strain in Europe and North America. Emerging antiviral therapies promise further increases in virological response, as well as improved tolerability, reduced duration of therapy, and will potentially eliminate the need for interferon use. This review highlights the main therapeutic agents used in current standard of care, including telaprevir and boceprevir. It goes on to evaluate the mechanisms of emerging drugs, their stage of development and response rates seen in research to date. Finally, it projects into the not too distant future to consider treatment strategies involving combinations of agents and interferon-free therapies, and in which patients they might prove most successful.
dc.formatapplication/pdf
dc.languageEnglish
dc.publisherWILEY
dc.subjectInfectious Diseases; Clinical Pharmacology and Therapeutics; Preventive Medicine
dc.titleCurrent and emerging antiviral treatments for hepatitis C infection
dc.typeJournal Article
dc.identifier.doi10.1111/j.1365-2125.2012.04419.x
melbourne.peerreviewPeer Reviewed
melbourne.affiliationThe University of Melbourne
melbourne.affiliation.departmentMedicine - Royal Melbourne Hospital
melbourne.source.titleBritish Journal of Clinical Pharmacology
melbourne.source.volume75
melbourne.source.issue4
melbourne.source.pages931-943
melbourne.publicationid196328
melbourne.elementsid530915
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612710
melbourne.contributor.authorLiew, Danny
melbourne.contributor.authorThompson, Alexander
melbourne.contributor.authorHellard, Margaret
dc.identifier.eissn1365-2125
melbourne.fieldofresearch320211 Infectious diseases
melbourne.fieldofresearch321402 Clinical pharmacology and therapeutics
melbourne.seocode200412 Preventive medicine
melbourne.accessrightsAccess this item via the Open Access location


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record